Navigation Links
Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
Date:8/1/2013

ioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare to treat patients with Gram-negative pneumonia.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.  Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Contact: Jennifer Ruddock/Nektar Therapeutics, (415) 482-5585


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... CVS Caremark Corporation (NYSE: CVS ) announced today ... in connection with its previously announced cash tender offers (the ... and all of its 6.250% Senior Notes due 2027 (the ... amount of its 6.125% Senior Notes due 2039, 5.750% Senior ... the "Maximum Tender Offer Notes" and together with the Any ...
(Date:8/21/2014)... /CNW/ - Bedrocan Cannabis Corp., previously Bedrocan Canada Inc. ... Board of Directors, enhancing executive oversight and strengthening ... leading licensed producer of medicinal cannabis in ... years, experience in producing and supplying government-regulated pharmaceutical-grade ... As previously announced in a ...
(Date:8/21/2014)... , Aug. 21, 2014  SI-BONE, Inc. ( ... that pioneered the use of the iFuse Implant System, ... for fusion of the sacroiliac (SI) joint, announced that ... update to its Lumbar Fusion Medical Policy No. 91590-R4 ... procedure.  The policy states that the fusion procedure, which ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
... QPT: TSX Venture Exchange, EDMONTON, May 02, 2007 ... Quest is pleased to provide an,update on the ... cancer. , Prostate cancer is the second leading ... 230,000 new cases and 30,000 deaths,per year. Current ...
... 2007 - Acorda Therapeutics, Inc.(R),(Nasdaq: ACOR) today ... trial,of Fampridine-SR in people with multiple sclerosis ... Andrew Goodman, M.D.,Director of the Multiple Sclerosis ... results on walking ability, leg,strength, spasticity and ...
Cached Medicine Technology:Quest PharmaTech's Prostate Cancer Program Update 2Quest PharmaTech's Prostate Cancer Program Update 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7
(Date:8/21/2014)... worlds of personal care and yoga are coming together ... products. BaliniSports will be shipping free samples ... qualifying purchases for a limited time. “The marriage between ... simply perfect,” said Ada Hung, founder and president of ... intended to give people in the yoga community a ...
(Date:8/21/2014)... Relias Learning, the leader in SaaS-based training ... markets, announced the latest release of its flagship LMS ... API. , “Supporting the Tin Can API ensures ... mobile learning capabilities and the ability to leverage the ... says Jim Triandiflou, CEO of Relias Learning. “To provide ...
(Date:8/21/2014)... peripheral neuropathy is important for the successful treatment ... Affiliated Hospital of Kunming Medical University, China, led ... sensitive index for nerve conduction studies in the ... with diabetes mellitus. Nerve conduction studies revealed that ... velocity was slower, and sensory nerve action potential ...
(Date:8/21/2014)... Bedros Keuilian’s Annual Fitness Business Summit is considered ... many people already earning seven-figure incomes. But his annual ... open to the owners of Keuilian’s own international fitness boot ... Body Boot Camp World Conference will also be attended by ... camp or are struggling with their own boot camp ...
(Date:8/21/2014)... Beach, FL (PRWEB) August 21, 2014 ... FZ LLC are pleased to announce the healthcare ... loaded onto operational/production servers. , The company anticipates ... as connections are established between individual physicians, via interfaces, ... collection platforms and finally with electronic data exchanges and ...
Breaking Medicine News(10 mins):Health News:Tom's of Maine Partner up with BaliniSports Yoga Apparel 2Health News:Relias Learning Announces Support for Tin Can API 2Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 2Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 3Health News:Grace Century’s Electronic Health Records Project, Quantum Innovations, Announces That PWeR® Healthcare Technology Platform is Ready for Deployment 2Health News:Grace Century’s Electronic Health Records Project, Quantum Innovations, Announces That PWeR® Healthcare Technology Platform is Ready for Deployment 3Health News:Grace Century’s Electronic Health Records Project, Quantum Innovations, Announces That PWeR® Healthcare Technology Platform is Ready for Deployment 4
... November 1, 2008 at this year,s liver ... 4, SAN FRANCISCO, Oct. 29 Two studies presented ... of Liver Diseases,paint a different picture of survival based on ... Researchers at the Baylor College of Medicine used a United ...
... at subclinical level and in early lactation ... would benefit producers, ... and diagnosing mastitis in dairy cows are not serving the,needs of ... at the recent annual meeting of the American,Association of Bovine Practitioners ...
... Medical,Technologies, Inc. (the "Company") (Nasdaq: CMED ... develops, manufactures and markets advanced in-,vitro diagnostic ... attending the,Credit Suisse Asian Healthcare Conference., ... China, China Medical Technologies, management team ...
... Handheld Device is First to Use IPL to ... 29 CLRS Technology today,announced the CLARO acne-clearing ... Drug Administration (FDA) for treatment of mild to ... use Intense Pulsed,Light (IPL) for treatment of acne, ...
... Calif., Oct. 29 What else could you ... Committee famously spent,on wardrobe and makeup for Gov. ... nurse who can be outfitted in scrubs,for just ... would outfit 15,000,RNs in scrubs," notes Geri Jenkins, ...
... Insurance Offers Insurance Guidance to Canadian Consumers , ... ... citizens of Canada face growing challenges due to economic issues ... cutbacks in Canada,s health care system and shrinking contributions by ...
Cached Medicine News:Health News:No Difference in Rate of Survival for Children of Different Races Undergoing Liver Transplantation, but Long-Term Results Not as Good for African-American Adults 2Health News:No Difference in Rate of Survival for Children of Different Races Undergoing Liver Transplantation, but Long-Term Results Not as Good for African-American Adults 3Health News:Dairy Veterinarians Highlight Need for Improved Methods for Detecting Mastitis 2Health News:CLARO Receives FDA-Clearance for Treatment of Acne 2Health News:Nurses Present Palin Clothing Line Website ... and Other Ways the Money Could Have Been Spent 2Health News:Leading Insurer Offers Education on How Supplemental Insurance Can Help Offset Challenging Economic Trends in Canadian Market 2Health News:Leading Insurer Offers Education on How Supplemental Insurance Can Help Offset Challenging Economic Trends in Canadian Market 3Health News:Leading Insurer Offers Education on How Supplemental Insurance Can Help Offset Challenging Economic Trends in Canadian Market 4Health News:Leading Insurer Offers Education on How Supplemental Insurance Can Help Offset Challenging Economic Trends in Canadian Market 5
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
... manufactured for use as a diluent for ... is for use on the Coulter® Counter ... IV, V, VI with three-part differential and ... The shelf life is two years from ...
Streck-Detergent IIIA is a balanced electrolyte solution for use as a rinsing and hemoglobin blanking diluent. It is manufactured specifically for use on the Abbott CELL-DYN® 1700 and 1800. The s...
... 12 Plus Retics is a 5-part differential ... for the Abbott CELL-DYN 3200, 3500, 3700 ... also contains nucleated red blood cells that ... CELL-DYN 4000. The assay contains automated and ...
Medicine Products: